Company profile
Bellus Health company profile
BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTA™, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA™. KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects..... For more information, log in to dureach.com to view the full company profile.
Business identity
- Website
- http://bellushealth.com
- Contact email
- [email protected]
- Phone number
- +1 (450)680-4500
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00051-00100 employees
- Founded
- 1993-06-17
Headquarters
- Headquarters
- Kingsey Falls, Quebec, Canada
- Postal code
- H7V 4A7
- Country code
- CA
- Continent
- North America